ALLMedicine™ Cavernous Sinus Thrombosis Center

Dec 18th, 2021 - To correlate the clinical, radiological, and histopathological features in Covid-associated Rhino-orbito-cerebral mucormycosis cases presenting with acute visual loss. Cross-sectional study. Covid-associated Rhino-orbito-cerebral mucormycosis case...

Oct 8th, 2021 - Cases of acute sphenoid sinusitis complicated by septic cavernous sinus (CS) thrombosis and internal carotid artery (ICA) stenosis are rarely reported. Different causative pathogens have been reported for this condition. We present two extremely r...

Sep 14th, 2021 - Cranial nerve injury is a described complication of Le Fort I osteotomy technique. The authors present the case of a 45-year-old patient that underwent bimaxillary orthognathic surgery and suffered unfavorable skull base fractures, which resulted ...

Aug 1st, 2021 - Cavernous sinus thrombosis is a very rare, typically septic thrombosis of the cavernous sinus, usually caused by nasal furuncles or bacterial sinusitis. Symptoms and signs include pain, proptosis, ophthalmoplegia, vision loss, papilledema, and fev...

Aug 1st, 2021 - Cavernous sinus thrombosis is a very rare, typically septic thrombosis of the cavernous sinus, usually caused by nasal furuncles or bacterial sinusitis. Symptoms and signs include pain, proptosis, ophthalmoplegia, vision loss, papilledema, and fev...

Sep 9th, 2019 - Infection with Candida auris likely led to panophthalmitis and vision loss in an immune compromised patient, according to a case report published online today in the Annals of Internal Medicine. Vinayak Shenoy, DO, and colleagues at Lenox Hill Hos...

Jul 10th, 2017 - The novel monoclonal antibody emicizumab substantially reduced bleeding risk in adolescents and adults with hemophilia A who have developed an immune response against standard factor VIII treatment, the phase III HAVEN trial showed. The drug, whic...

Jul 10th, 2017 - Once-weekly prophylactic therapy with emicizumab (ACE910) was associated an 87% lower rate of treated bleeding than no prophylaxis among patients with hemophilia A with inhibitors in the open-label, phase III HAVEN 1 trial. After a median 24 weeks.

Jul 10th, 2017 - Once-weekly prophylactic therapy with emicizumab (ACE910) was associated an 87% lower rate of treated bleeding than no prophylaxis among patients with hemophilia A with inhibitors in the open-label, phase III HAVEN 1 trial. After a median 24 weeks.